Navigation Links
New Studies Show Popular Heartburn Medications Moderate the Effect of Taking Widely Prescribed Heart Drug
Date:5/6/2009

o address a related issue that has raised questions about the PPI/clopidogrel interaction, the researchers also looked at whether or not PPIs independently increase the risk of a CV event. The results of this study found that there was no independent effect from taking a PPI in the absence of clopidogrel. The study included 1,641 patients who had undergone a stent procedure but were not taking clopidogrel and compared CV event hospitalizations of patients on a PPI to those not taking a PPI. These findings were recently presented at the American Heart Association's Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular and Stroke (QCOR).

"Our study, along with a 2007 FDA review and other researchers' work, provides strong evidence that PPIs do not independently raise cardiovascular risks for stent patients and further strengthens the observation that this interaction exists between PPIs and clopidogrel and impairs the effectiveness of the antiplatelet drug," said Epstein. "Given the totality of the evidence generated on this interaction and the known benefits of clopidogrel in reducing the risk of death, heart attack and stroke after coronary stenting, patients and their physicians should continue to trust in the use of this medication and consider a PPI only when clearly indicated."

About Medco

Medco Health Solutions, Inc (NYSE: MHS) is a leading health care company, serving the needs of more than 60 million people. Medco, the world's most advanced pharmacy(R), provides clinically driven pharmacy services designed to improve the quality of care and lower total health care costs for private and public employers, health plans, labor unions and government agencies of all sizes, and for individuals served by Medicare Part D Prescription Drug Plans. Through its unique Medco Therapeutic Res
'/>"/>

SOURCE Medco Health Solutions, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting
2. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
3. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
4. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
5. Alimera Sciences Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
6. Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX
7. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
8. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
9. Studies Show Combination Laser Therapy Effective At Clearing Acne, Reducing Oil Production
10. Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield
11. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "Global Multiple Sclerosis Drugs Market 2014-2018" report to ... chronic, inflammatory medical condition that results in demyelination, axonal ... of an abnormal response by the immune system, which ... is a potentially debilitating disease in which the damage ...
(Date:8/29/2014)...  Abaxis, Inc. (NasdaqGS: ABAX ), a ... to the medical, research and veterinary markets, announced today ... Officer, will present at the CL King 12 th ... 9, 2014 at 12:30 p.m. ET. The conference will ... New York City . ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 /PR ... ("DelMar" "the Company") today announced the filing of June ... changed its fiscal year end to June 30th in ... stock on a national securities exchange in the timeliest ... with the United States Securities Exchange Commission can be ...
Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... April 14, 2011 Oxford Finance Corporation (Oxford), a ... a $2 million equipment loan with Synta Pharmaceuticals Corp. ... compounds for use in Synta,s ongoing clinical trials in ... "Synta Pharmaceuticals has a diverse drug pipeline, including ...
... (NYSE: BT ) shared its vision of ... cloud computing strategies to pharma research at the Bio-IT ... This vision reflects BT,s strong capabilities and increasing specialization ... world,s leading pharmaceutical companies rely on BT to support ...
Cached Medicine Technology:Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp. 2BT Pushes for R&D Innovation at Bio-IT World Conference 2BT Pushes for R&D Innovation at Bio-IT World Conference 3
(Date:8/29/2014)... Pursuing its deepest desires to help build ... stunning new design that promises to redefine the global ... surrogacy platform has witnessed a 42 percent increase in ... month, the FindSurrogateMother.com community is formed by hopeful parents ... — the precious gift of life. , Whether intended ...
(Date:8/29/2014)... News) -- If you have bunions, taking care of them ... expert says. A bunion is a bump that forms ... tissue moves out of place and extends beyond the normal ... pain and may require surgery to correct, said Brent Rosenthal, ... Freehold, N.J. To prevent bunions, avoid wearing shoes with ...
(Date:8/29/2014)... NEW YORK August 29, 2014 - Despite US ... obesity, there are many barriers, several of which may ... study by researchers at NYU Langone Medical Center published ... General Internal Medicine ( JGIM ). , David ... Department of Internal Medicine at NYU Langone, and colleagues ...
(Date:8/29/2014)... AURORA, Colo. (Sept. 2, 2014) A team of ... has reported the breakthrough discovery of a process to ... patients. These findings could have implications that extend beyond ... and autoimmune diseases., In an article published ... the Charles C. Gates Center for Regenerative Medicine and ...
(Date:8/29/2014)... 29, 2014 Today, NBC’s “The ... who profiled a handful of safe, back to ... Research. This year, many schools will include earphones ... innovator of hearing wellness solutions, offers the best ... Earphones, offered in yellow, pink and black, sound ...
Breaking Medicine News(10 mins):Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 3Health News:Take Steps to Control Bunions 2Health News:Options for weight loss your primary care doctor might not know about 2Health News:CU scientists' discovery could lead to new cancer treatment 2Health News:The Today Show Features ETY•Kids® Safe-Listening Earphones by Etymotic 2
... N.Y., Oct. 8 Moog Inc. (NYSE:,MOG.A and ... are adopting,the Moog brand name. The organizations and ... to an expanded product portfolio within a,single, well-established ... continue to be associated with the,products, this event ...
... by Leading Architectural Firms, LISBON, Portugal ... weeks after,awarding two Johns Hopkins University scientists ... for their research in combating blindness, the,Antonio ... medical,research with the groundbreaking of its 300,000-square-foot ...
... safe substitutes for authentic,FDA approved injectables, NEW ... cosmetic injectables are a threat to your looks,and ... Safety. "The,growing acceptance of cosmetic injections for their ... cautions," says Coalition,leader, plastic surgeon Jeffrey Kenkel, MD ...
... Hodgkin lymphoma, a common form of cancer of the ... blood cells (B cells), but have lost a considerable ... phenotype and the characteristics of Hodgkin lymphoma cells are ... Delbrck Center for Molecular Medicine, MDC, Berlin-Buch and Charit ...
... of Defense has awarded The University of Texas Health ... conduct a multi-center clinical trial that could lead to ... both soldiers and civilians -- who require massive blood ... Sciences (CCTS) is contracting with the U.S. Army Institute ...
... closer to understanding the spread of deadly diseases such ... bacteria respond to stress. , The research, published in ... Science , details how a huge molecule called a ... , Scientists from the University of Newcastle in ...
Cached Medicine News:Health News:World Renowned Champalimaud Foundation Extends its Mission with Groundbreaking for Cutting-Edge Research Center 2Health News:World Renowned Champalimaud Foundation Extends its Mission with Groundbreaking for Cutting-Edge Research Center 3Health News:Illegal Botox Scammers a Public Threat 2Health News:Illegal Botox Scammers a Public Threat 3Health News:Illegal Botox Scammers a Public Threat 4Health News:Illegal Botox Scammers a Public Threat 5Health News:Hodgkin lymphoma -- new characteristics discovered 2Health News:Hodgkin lymphoma -- new characteristics discovered 3Health News:UT researchers to study massive transfusion at major trauma centers 2Health News:Protection for stressed-out bacteria identified 2
Futuremeds Astotherm Plus Blood and Fluid Warmers meet American Blood Bank and ECRI standards., ,Astotherm is a durable warmer you can rely on for many years....
... anesthesia solution for the MRI environment , ... ,The Narkomed MRI-2 is the only ... monitor, designed and engineered to perform, without distance ... environments of up to 3.0 Tesla. This feature ...
... Narkomed GS provides high quality ventilation ... The proven technologies of the AV2+ ... the Narkomed GS user-friendly and intuitive. ... quality Narkomed GS is the perfect ...
... facilities where space is a premium Fabius ... delivery technologies with an ergonomic and compact ... of the Draeger Infinity patient monitoring range ... environment that is a sound investment into ...
Medicine Products: